BioNTech Enters ADC Field with US$1.6 B+ DualityBio Licensing Deal

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 4 (Table of Contents)

Published: 6 Apr-2023

DOI: 10.3833/pdr.v2023.i4.2778     ISSN: 1756-7874

Section: Licensing



In yet another deal to diversify its portfolio, BioNTech has entered into a licensing and collaboration agreement with Duality Biologics to develop, manufacture and commercialise two antibody-drug conjugate (ADC) therapies...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details